Allergy & Immunology
Perspective: Covid-19 vaccines may cause mild side effects, experts say, stressing need for education, not alarm
28 Jul, 2020 | 07:44h | UTC
Perspective: A vaccine reality check
28 Jul, 2020 | 07:45h | UTCA Vaccine Reality Check – The Atlantic
What scientists are learning about how long Covid-19 immunity lasts
24 Jul, 2020 | 09:22h | UTCWhat scientists are learning about how long Covid-19 immunity lasts – Vox
Observational study: Glucocorticoid treatment linked to reduced mortality in patients with Covid-19 and initial C-reactive protein ≥20 mg/dL
23 Jul, 2020 | 08:49h | UTCCommentaries: A blood test may show which COVID-19 patients steroids will help — or harm – Science News AND Common blood test identifies benefits and risks of steroid treatment in COVID-19 patients – Albert Einstein College of Medicine
Perspective: Covid-19 vaccines with ‘minor side effects’ could still be pretty bad
23 Jul, 2020 | 08:37h | UTCCovid-19 Vaccines With ‘Minor Side Effects’ Could Still Be Pretty Bad – Wired
Controversial ‘human challenge’ trials for COVID-19 vaccines gain support
23 Jul, 2020 | 08:34h | UTCControversial ‘human challenge’ trials for COVID-19 vaccines gain support – Science
Coronavirus vaccines leap through safety trials — but which will work is anybody’s guess
23 Jul, 2020 | 08:39h | UTCCoronavirus vaccines leap through safety trials — but which will work is anybody’s guess – Nature
Rapid decay of Anti–SARS-CoV-2 antibodies in persons with mild Covid-19
22 Jul, 2020 | 02:35h | UTC
SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls
22 Jul, 2020 | 02:22h | UTCSARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls – Nature
Commentaries: New Data on T Cells and the Coronavirus – Science Translational Medicine AND Scientists uncover SARS-CoV-2-specific T cell immunity in recovered COVID-19 and SARS patients – Duke-NUS Medical School AND Expert reaction to study looking at SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS and uninfected controls from data from Singapore – Science Media Centre
Phase 2 randomized trial: immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults
21 Jul, 2020 | 09:29h | UTCCommentaries: China’s Ad5 vectored COVID-19 vaccine safe and induces immune response – News Medical AND CanSino COVID-19 vaccine generates immune response in 90% of patients – UPI
Related Commentary on Twitter
https://twitter.com/TheLancet/status/1285209554775617536
Editorial: encouraging results from phase 1/2 COVID-19 vaccine trials
21 Jul, 2020 | 09:35h | UTCEncouraging results from phase 1/2 COVID-19 vaccine trials – The Lancet
Commentaries: Promising early findings for 2 more COVID-19 vaccines – CIDRAP AND Expert reaction to two vaccine candidate studies: a phase 1/2 trial of the University of Oxford’s ChAdOx1 vaccine candidate; and a phase 2 trial of China’s Ad5-vectored COVID-19 vaccine candidate – Science Media Centre
Phase 1/2 randomized trial: safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2
21 Jul, 2020 | 09:33h | UTCCommentaries: New study reveals Oxford coronavirus vaccine produces strong immune response – University of Oxford AND Oxford’s Covid-19 vaccine appears safe and induces immune response, early results suggest, but more research is needed – CNN AND Early Oxford-AstraZeneca Coronavirus Vaccine Data ‘Encouraging,’ Scientists Say – NPR
Related Commentary on Twitter
NEW—UK’s #COVID19 vaccine is safe and induces an immune reaction, according to preliminary results https://t.co/rDPlB9fDKr pic.twitter.com/z2t9Aubjim
— The Lancet (@TheLancet) July 20, 2020
Randomized trial: dexamethasone in hospitalized patients with Covid-19
20 Jul, 2020 | 08:18h | UTCCommentary: Trial data support dexamethasone, but not hydroxychloroquine, for COVID-19 – CIDRAP
Related Commentary on Twitter
A randomized controlled trial testing dexamethasone for Covid-19 (the RECOVERY trial) showed that, compared with usual care, this corticosteroid drug reduced 28-day mortality in hospitalized patients. #COVID19 #SARSCoV2
— NEJM (@NEJM) July 18, 2020
Is coronavirus reinfection possible?
20 Jul, 2020 | 08:01h | UTCIs Coronavirus Reinfection Possible? – Self
Serology testing in the COVID-19 pandemic response
20 Jul, 2020 | 08:02h | UTCSerology testing in the COVID-19 pandemic response – The Lancet Infectious Diseases
Why those most at risk of COVID-19 are least likely to respond to a vaccine
20 Jul, 2020 | 07:55h | UTCWhy those most at risk of COVID-19 are least likely to respond to a vaccine – National Geographic
How effective does a COVID-19 coronavirus vaccine need to be to stop the pandemic? A new study has answers
17 Jul, 2020 | 08:50h | UTC
Related Commentary on Twitter
How 'good' does a COVID-19 coronavirus vaccine need to be to stop the pandemic? Study: “If only 75% of the population gets vaccinated, the vaccine efficacy would have to be around 70%.” So we still might need a “Plan B” https://t.co/aoHu4L0SYU
— Paul Glasziou (@PaulGlasziou) July 16, 2020
Open letter: challenge trials for COVID-19
17 Jul, 2020 | 08:48h | UTCChallenge Trials for COVID-19 – 1 Day Sooner
Commentary: Scientists call for volunteers to be infected with the coronavirus to test vaccines – CNBC
An mRNA vaccine against SARS-CoV-2 — preliminary report
15 Jul, 2020 | 08:25h | UTCAn mRNA Vaccine against SARS-CoV-2 — Preliminary Report – New England Journal of Medicine
Editorial: The Covid-19 Vaccine-Development Multiverse – New England Journal of Medicine
Commentaries: Experimental COVID-19 vaccine safe, generates immune response – NIH News Release AND First data for Moderna Covid-19 vaccine show it spurs an immune response – STAT
Perspective – “My patient caught Covid-19 twice. So long to herd immunity hopes”
14 Jul, 2020 | 08:19h | UTCMy patient caught Covid-19 twice. So long to herd immunity hopes. – Vox
A new understanding of herd immunity
14 Jul, 2020 | 08:23h | UTCA New Understanding of Herd Immunity – The Atlantic
A perspective on potential antibody-dependent enhancement of SARS-CoV-2
14 Jul, 2020 | 08:17h | UTCA perspective on potential antibody-dependent enhancement of SARS-CoV-2 – Nature
Related Commentary on Twitter
The enhancement of disease by antibody-dependent mechanisms (ADE) looms as a/the major concern for #SARSCoV2 vaccines and neutralizing antibodies. A new @nature perspective, explainer, and details of what needs to be donehttps://t.co/0c1Nx92B6v pic.twitter.com/DoflhwpR9A
— Eric Topol (@EricTopol) July 13, 2020
Case Reports: 2 Adults with Kawasaki-like Multisystem Inflammatory Syndrome Associated with COVID-19
13 Jul, 2020 | 00:05h | UTCCase Report 1: An adult with Kawasaki-like multisystem inflammatory syndrome associated with COVID-19 – The Lancet
Case Report 2: An adult presentation consistent with PIMS-TS – The Lancet Rheumatology
Related Commentary on Twitter
First reports of Kawasaki-like #SARSCoV2 multi-system inflammatory syndrome in adultshttps://t.co/FYNWlxdk9q @TheLancet https://t.co/lnHMUxA7Ux @TheLancetRheum
21 yo in London, 45 yo in New York City pic.twitter.com/lLmSRzBjs4— Eric Topol (@EricTopol) July 11, 2020
Observational Analysis: BCG Vaccine and COVID-19
13 Jul, 2020 | 00:02h | UTCCommentaries: Expert reaction to study looking at BCG vaccination programmes and COVID-19 deaths in different countries – Science Media Centre AND Preliminary study suggests tuberculosis vaccine may be limiting COVID-19 deaths – Virginia Tech
[Abstract Only] Randomized Trial: Intravenous Cetirizine Versus Intravenous Diphenhydramine for the Treatment of Acute Urticaria
12 Jul, 2020 | 23:57h | UTCIntravenous Cetirizine Versus Intravenous Diphenhydramine for the Treatment of Acute Urticaria: A Phase III Randomized Controlled Noninferiority Trial – Annals of Emergency Medicine (link to abstract – $ for full-text)